
Hong Kong
Hong Kong has a long history of international research with sophisticated infrastructure and resources across all phases. A small, densely populated area, Hong Kong’s world‑class hospitals offer excellent recruitment potential. Hong Kong has a long and impressive track record of conducting global clinical trials. Since the introduction of ICH GCP in 1996, Hong Kong has participated in over 1000 global clinical trials. Hong Kong has had a history of high‑quality clinical research output and plays a role in scientific leadership in Asia.
Hong Kong has excellent infrastructure in terms of transportation, workforce and legal framework. Hong Kong has an outstanding healthcare system, as indicated by one of the lowest infant mortality rates and the longest life expectancy in the world. There are 42 public hospitals that provide 90% of the medical care in Hong Kong.
Hong Kong is officially recognized by China State Food and Drug Administration for conducting clinical trials for drug registration purposes in mainland China in certain therapeutic areas. There is strong government support for clinical research, with the recent example being the set up of two Phase I centers at leading teaching hospitals in Hong Kong.
Clinical trial data from Hong Kong can be used to file new drug applications, making Hong Kong a gateway to mainland China.
What are the benefits of conducting clinical trials in Hong Kong?
- Fast approval timeline of 3‑6 months
- Clinical data from Hong Kong is recognized globally
- Two‑Phase 1 Clinical Trial Centers (both accredited by CFDA)
- Hong Kong data can be used to file New Drug Application in CFDA
- Unrestricted import and export of biological specimens
- Developed infrastructure
- A strong presence of academic institutions
- High‑quality investigators
- English as the official language
Why is Emerald Clinical the CRO of choice for our sponsors in Hong Kong?
- Well established site network
- Experienced team on local regulations requirement
- Engagement with key opinion leaders (oncology and renal scientific leaders)